Lidocaine patches could be an alternative pain solution. Lidocaine patches may be effective for patients who are in pain but are looking to avoid drugs that could be addictive. Whenever a patient ...

The results of this exploratory study suggest that Lidoderm can alleviate the pain associated with OA of the knee. "The results of this exploratory study suggest that Lidoderm can alleviate the pain ...

The US District Court for the Northern District of California certified classes of direct purchasers and end-payers in a pay-for-delay multidistrict litigation involving Lidoderm. In re Lidoderm ...

Pharma has its latest pay-for-delay settlement. In a pair of deals with two plaintiff classes over generic Lidoderm delays, Endo, Teva and Japanese drugmaker Teikoku Seiyaku have agreed to fork over ...

A preclinical study commissioned by Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company") concluded that the Company's investigational lidocaine transdermal patch compares favorably to the Lidoderm ...

CHADDS FORD, Pa., March 31, 2005 – Today at the 24th Annual Scientific Meeting of the American Pain Society, Endo Pharmaceuticals Inc. released new clinical trial data which found patients receiving ...

SAN FRANCISCO (CN) - A federal judge on Thursday finalized two class action settlements worth $270 million, ending four years of litigation over an alleged antitrust conspiracy to keep a generic form ...

PHILADELPHIA (Legal Newsline) – Endo Health Solutions Inc. and its subsidiary, Endo Pharmaceuticals, have agreed to a $171.9 million settlement with the federal government to resolve off-label ...

opioids In a meta-analysis, researchers evaluated whether a lidocaine patch is beneficial for postoperative pain as an option for multimodal analgesia. The use of lidocaine patches for postoperative ...

Amneal has received Food and Drug Administration approval for its lidocaine patch 5%. The product is a generic of Lidoderm Patch 5%. “We are pleased to announce the approval for the Lidocaine Patch, 5 ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from ...